Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/1b study of CPI 006 as a single agent, in combination with ciforadenant and pembrolizumab in patients with advanced cancer

X
Trial Profile

A phase 1/1b study of CPI 006 as a single agent, in combination with ciforadenant and pembrolizumab in patients with advanced cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mupadolimab (Primary) ; Ciforadenant; Pembrolizumab
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Apr 2021 According to a Corvus Pharmaceuticals media release, the company plans to expand a cohort which is based on the identification of tumor types with biologic features best addressed by the unique mechanism of action of CPI-006.
    • 12 Oct 2020 New trial record
    • 05 Oct 2020 According to a Corvus Pharmaceuticals media release, the company has entered into a strategic collaboration with Angel Pharmaceuticals that will enable the development and commercialization of its pipeline of precisely targeted investigational medicines in China.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top